Bioassay and Immunogenicity Assessements from Abzena

Description

Our comprehensive suite of bioassay solutions includes both established assays and custom assay development matched to your individual program needs.

Our bioassay services include:
  • Target validation
  • Hittolead screening
  • Antibody Design & Development
  • Specificity & tissue profiling
  • Mode of action
  • Immunogenicity & Safety assessment
  • Biologics Manufacturing Potency & Batch Release
  • Manufacturing – Potency & Batch release
What sets Abzena's bioassay and analytical development services apart?
  • Stateoftheart laboratories with an extensive range of biophysical equipment and capabilities
  • Extensive experience in supporting manufacturability, developability assessment, and lead candidate selection for a wide range of modalities including mAbs, bispecifics, and bioconjugates
  • Expertise in protein characterization and proteomics provide an indepth molecular understanding, including identification of posttranslational modifications and degradation sites
  • Analytical capabilities to support bioconjugate programs including DAR and conjugation site identification as well as serum stability and payload release studies and free payload analysis
  • Analytical capabilities to support CLD programs, including determination of critical or product quality attributes and reference standard characterization
  • Significant immunoproteomics expertise supports the derisking of potential immunogenicity of biotherapeutics and or to enhance vaccine development
  • We offer a full range of phase appropriate solutions, from simple bioassays with high accuracy and precision to complex coculture primary cell models for mode of action studies
  • Comprehensive suite of functional bioassays with over 30 offtheshelf assays, as well as tailored solutions to answer specific questions that offtheshelf assays may not be able to answer
  • Investigative approach to provide data early in the development process allowing informed decision making on whether to progress or kill a program, translating to significant time/cost savings
  • Extensive experience with a wide range of modalities, including mAbs, ADCs, AOCs, bispecifics and immunomodulators